Cancer, a heterogeneous group of diseases characterized by uncontrolled cell proliferation, remains a significant global health challenge.  While traditional cancer treatments offer broad-spectrum efficacy, their effectiveness is often limited by inherent inter-patient variability and significant side effects. Recent breakthroughs in understanding the genetic underpinnings of cancer have revolutionized our approach to treatment, paving the way for personalized medicine. This research paper explores the burgeoning field of cancer genetics and its impact on the development of individualized therapeutic strategies.  Advances in next-generation sequencing (NGS) technologies have facilitated the identification of numerous driver mutations and genomic alterations, allowing for precise characterization of tumor heterogeneity at an unprecedented level.  This detailed genetic profiling is now informing the development of targeted therapies, including kinase inhibitors, immunotherapy, and gene editing technologies, which offer improved efficacy and reduced toxicity compared to conventional chemotherapy.  Furthermore, the growing understanding of tumor microenvironment and its interaction with the host genome is enhancing the predictive power of genomic profiling, leading to more accurate treatment selection and improved patient outcomes. This review will examine these recent advances, their clinical implications, and the remaining challenges in translating these discoveries into effective and widely accessible personalized cancer care.